전남대학교 중앙도서관

  • 중앙도서관
  • 여수캠퍼스도서관
  • 법학도서관
  • 치의학도서관
  • 의학도서관

링크메뉴

  • 화면키우기 화면줄이기 화면크기 원래대로
  • S
  • HOME
  • 로그인
  • 전남대
  • ENG
  • CHN

주메뉴

전체메뉴

전자자료 상세검색

전자자료 상세검색

통합검색
상세검색
검색어 [키워드: "Valero JG"]
총 20건 
※ 중복 레코드가 제거된 검색 결과가 표시됩니다.
1/2 페이지 RSS 엑셀파일 출력
검색결과수정
  • 검색범위확장
    • Full Text내 키워드 확장
    • 관련 주제어 확장

    재검색

  • 검색결과제한
    • 원문(Full Text)
    • Peer-Reviewed 학술지
    • 발행년 -

    재검색

  • 자료유형
    • Academic Journals (20)

    재검색

  • 주제
    • lymphoma, follicular (4)
    • antineoplastic agents (3)
    • apoptosis (2)

    더보기

    재검색

  • 간행물
    • plos one (3)
    • cancers (2)
    • haematologica (2)

    더보기

    재검색

  • 출판사
    • public library of science (3)
    • bmj publishing group ltd (2)
    • ferrata storti foundation (2)

    더보기

    재검색

  • 언어
    • english (20)

    재검색

  • 수록데이터베이스
    • MEDLINE (19)
    • Science Citation Index Expanded (1)

    재검색

  • PQDTSearch
  • CAJSearch
  • RISSSearch
  • PsycINFOSearch

 

2
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target. 미리보기

학술저널

issue
Blood cancer journal [Blood Cancer J] 2024 May 02; Vol. 14 (1), pp. 75. Date of Electronic Publication: 2024 May 02.
Author
Dobaño-López C; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Valero JG; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Araujo-Ayala F; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Nadeu F; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Gava F; Université de Toulouse, INSERM, CNRS, Université de Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.
Faria C; Université de Toulouse, INSERM, CNRS, Université de Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.
Norlund M; IMACTIV-3D, Toulouse, France.
Morin R; IMACTIV-3D, Toulouse, France.
Bernes-Lasserre P; IMACTIV-3D, Toulouse, France.
Arenas F; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Grau M; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
López C; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; University of Barcelona, Medical School, Barcelona, Spain.
López-Oreja I; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Secció Hematopatologia, Servei d'Anatomia Patològica, Hospital Clínic, Barcelona, Spain.
Serrat N; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Martínez-Farran A; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Hernández L; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Playa-Albinyana H; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Giménez R; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Beà S; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; University of Barcelona, Medical School, Barcelona, Spain.; Secció Hematopatologia, Servei d'Anatomia Patològica, Hospital Clínic, Barcelona, Spain.
Campo E; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; University of Barcelona, Medical School, Barcelona, Spain.; Secció Hematopatologia, Servei d'Anatomia Patològica, Hospital Clínic, Barcelona, Spain.
Lagarde JM; IMACTIV-3D, Toulouse, France.
López-Guillermo A; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; University of Barcelona, Medical School, Barcelona, Spain.; Servei Hematologia, Hospital Clínic, Barcelona, Spain.
Magnano L; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; IMACTIV-3D, Toulouse, France.; University of Barcelona, Medical School, Barcelona, Spain.; Servei Hematologia, Hospital Clínic, Barcelona, Spain.
Colomer D; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; University of Barcelona, Medical School, Barcelona, Spain.; Secció Hematopatologia, Servei d'Anatomia Patològica, Hospital Clínic, Barcelona, Spain.
Bezombes C; Université de Toulouse, INSERM, CNRS, Université de Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France. christine.bezombes@inserm.fr.
Pérez-Galán P; Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. pperez@recerca.clinic.cat.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain. pperez@recerca.clinic.cat.
DB Label
Database : MEDLINE
원문보기
OA (Springer)  OA (Nature)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
3
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine. 미리보기

학술저널

issue
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Oct; Vol. 11 (10).
Author
Faria C; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.
Gava F; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.
Gravelle P; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.; Department of Pathology, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.
Valero JG; Department of Hemato-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Dobaño-López C; Department of Hemato-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Van Acker N; Department of Pathology, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.; Imag'IN Platform, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.
Quelen C; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.; Department of Pathology, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.
Jalowicki G; IUCT-Oncopole, Toulouse, France.; Department of Pathology, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.
Morin R; IMACTIV3D, Toulouse, France.
Rossi C; Department of Hematology, Hôpital François Mitterrand and U1231 INSERM, Dijon, France.
Lagarde JM; IMACTIV3D, Toulouse, France.
Fournié JJ; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.
Ysebaert L; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.; Department of Hematology, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.
Laurent C; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.; Department of Pathology, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.; Imag'IN Platform, Institut Universitaire du Cancer de Toulouse, CHU Toulouse, Toulouse, France.
Pérez-Galán P; Department of Hemato-Oncology, IDIBAPS, Barcelona, Spain christine.bezombes@inserm.fr PPEREZ@recerca.clinic.cat.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Bezombes C; Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France christine.bezombes@inserm.fr PPEREZ@recerca.clinic.cat.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.
DB Label
Database : MEDLINE
원문보기
Open Access (PubMed Central)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
4
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses. 미리보기

학술저널

issue
Leukemia [Leukemia] 2023 Jun; Vol. 37 (6), pp. 1311-1323. Date of Electronic Publication: 2023 Apr 08.
Author
Araujo-Ayala F; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Dobaño-López C; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Valero JG; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Nadeu F; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Gava F; Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Toulouse, France.; Université de Toulouse, Inserm, CNRS, Université Toulouse IIIPaul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.
Faria C; Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Toulouse, France.; Université de Toulouse, Inserm, CNRS, Université Toulouse IIIPaul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.
Norlund M; IMACTIV-3D, Toulouse, France.
Morin R; IMACTIV-3D, Toulouse, France.
Bernes-Lasserre P; IMACTIV-3D, Toulouse, France.
Serrat N; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.
Playa-Albinyana H; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Giménez R; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Campo E; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Hospital Clínic, Barcelona, Spain.; University of Barcelona, Medical School, Barcelona, Spain.
Lagarde JM; IMACTIV-3D, Toulouse, France.
López-Guillermo A; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Hospital Clínic, Barcelona, Spain.; University of Barcelona, Medical School, Barcelona, Spain.
Gine E; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Hospital Clínic, Barcelona, Spain.
Colomer D; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Hospital Clínic, Barcelona, Spain.; University of Barcelona, Medical School, Barcelona, Spain.
Bezombes C; Centre de Recherches en Cancérologie de Toulouse (CRCT), INSERM UMR1037, Toulouse, France.; Université de Toulouse, Inserm, CNRS, Université Toulouse IIIPaul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.; IUCT-Oncopole, Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.; Institut Carnot Lymphome CALYM, Pierre-Bénite, France.
Pérez-Galán P; Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Barcelona, Spain. pperez@recerca.clinic.cat.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain. pperez@recerca.clinic.cat.
DB Label
Database : MEDLINE
원문보기
Full Text (Nature)  등재 - Web of Science (SCIE)  조회 - Impact Factor (JCR) 
5
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. 미리보기

학술저널

issue
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Feb; Vol. 11 (2).
Author
Melchor J; Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain.; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Garcia-Lacarte M; Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain.; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Grijalba SC; Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Arnaiz-Leché A; Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Pascual M; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Panizo C; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Department of Hematology, Clinica Universidad de Navarra, Pamplona, Spain.; Current address: Department of Hematology and Hemotherapy, Hospital Universitario Donostia, San Sebastián, Spain.
Blanco O; Department of Pathology, Universidad de Salamanca, Salamanca, Spain.
Segura V; Bio-informatic Unit, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Current address: Data Intelligence Unit, Techedge Spain, Madrid, Spain.
Novo FJ; Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Valero JG; Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Pérez-Galán P; Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Martinez-Climent JA; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Roa S; Department of Biochemistry and Genetics, Universidad de Navarra, Pamplona, Spain sroa@unav.es.; Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
DB Label
Database : MEDLINE
원문보기
Open Access (PubMed Central)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
6
Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway. 미리보기

학술저널

issue
The FEBS journal [FEBS J] 2022 May; Vol. 289 (9), pp. 2540-2561. Date of Electronic Publication: 2021 Nov 28.
Author
Beà A; Cell Signaling & Apoptosis Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), Universitat de Lleida, Spain.
Valero JG; Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Barcelona, Spain.
Irazoki A; Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat de Barcelona, Spain.
Lana C; Cell Signaling & Apoptosis Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), Universitat de Lleida, Spain.
López-Lluch G; Andalusian Center of Developmental Biology, Pablo de Olavide University, Sevilla, Spain.; Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Sevilla, Spain.
Portero-Otín M; Department of Experimental Medicine, IRBLleida, University of Lleida, Lleida, Spain.
Pérez-Galán P; Department of Hematology-Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Barcelona, Spain.
Inserte J; Laboratory of Experimental Cardiology, Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, Spain.; Centro de Investigación Biomédica en Red-CV (CIBER-CV), Barcelona, Spain.
Ruiz-Meana M; Laboratory of Experimental Cardiology, Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona, Spain.; Centro de Investigación Biomédica en Red-CV (CIBER-CV), Barcelona, Spain.
Zorzano A; Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat de Barcelona, Spain.
Llovera M; Cell Signaling & Apoptosis Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), Universitat de Lleida, Spain.
Sanchis D; Cell Signaling & Apoptosis Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), Universitat de Lleida, Spain.
DB Label
Database : MEDLINE
원문보기
Full Text Full Text (원문보기) PLinkFull Text (원문보기) Full Text (Wiley-DB)  등재 - Web of Science (SCIE)  조회 - Impact Factor (JCR) 
7
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. 미리보기

학술저널

issue
British journal of haematology [Br J Haematol] 2022 Feb; Vol. 196 (3), pp. 589-598. Date of Electronic Publication: 2021 Oct 10.
Author
Dlouhy I; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.
Karube K; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Cell Biology & Pathology Department, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
Enjuanes A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Salaverria I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Nadeu F; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Ramis-Zaldivar JE; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Valero JG; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Rivas-Delgado A; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.
Magnano L; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.
Martin-García D; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Pérez-Galán P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Clot G; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Rovira J; Department of Hematology, Hospital Clínic, Barcelona, Spain.
Jares P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Balagué O; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Giné E; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.
Mozas P; Department of Hematology, Hospital Clínic, Barcelona, Spain.
Briones J; Hospital de Sant Pau, Barcelona, Spain.
Sancho JM; ICO-Hospital Germans Trias i Pujol, Badalona, Spain.
Salar A; Hospital del Mar, Barcelona, Spain.
Mercadal S; ICO-Hospital Duran i Reynals, L'Hospitalet de LLobregat, Spain.
Alcoceba M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Hospital Clínico Universitario, Salamanca, Spain.
Valera A; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Campo E; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; Institut d`Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.
López-Guillermo A; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Tumores Hematológicos, Madrid, Spain.; University of Barcelona, Barcelona, Spain.
DB Label
Database : MEDLINE
원문보기
Full Text (Wiley-DB)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
8
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. 미리보기

학술저널

issue
Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2635-2649. Date of Electronic Publication: 2021 Mar 17.
Author
Valero JG; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Matas-Céspedes A; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Arenas F; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Rodriguez V; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Garvan Institute of Medical Research, Sydney, Australia.
Carreras J; Department of Pathology, Tokai University, School of Medicine, Isehara, Kanagawa, Japan.
Serrat N; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.
Guerrero-Hernández M; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Department of Gene Regulation, Stem Cells and Cancer Center for Genomic Regulation (CRG-PRBB), Barcelona, Spain.
Yahiaoui A; Gilead Sciences, Inc, Foster City, USA.
Balagué O; Hematopathology Unit, Pathology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.
Martin S; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Capdevila C; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.
Hernández L; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.
Magnano L; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Department of Hematology, Hospital Clinic -IDIBAPS, Barcelona, Spain.
Rivas-Delgado A; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Department of Hematology, Hospital Clinic -IDIBAPS, Barcelona, Spain.
Tannheimer S; Gilead Sciences, Inc, Foster City, USA.
Cid MC; Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain.
Campo E; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Hematopathology Unit, Pathology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.; University of Barcelona, Medical School, Barcelona, Spain.
López-Guillermo A; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Department of Hematology, Hospital Clinic -IDIBAPS, Barcelona, Spain.; University of Barcelona, Medical School, Barcelona, Spain.
Colomer D; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain.; Hematopathology Unit, Pathology Department, Hospital Clínic-IDIBAPS, Barcelona, Spain.; University of Barcelona, Medical School, Barcelona, Spain.
Pérez-Galán P; Department of Hematology-Oncology, IDIBAPS, Barcelona, Spain. pperez@clinic.cat.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain. pperez@clinic.cat.
DB Label
Database : MEDLINE
원문보기
Full Text (Nature)  등재 - Web of Science (SCIE)  조회 - Impact Factor (JCR) 
9
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma. 미리보기

학술저널

issue
Cancers [Cancers (Basel)] 2021 Mar 24; Vol. 13 (7). Date of Electronic Publication: 2021 Mar 24.
Author
Gava F; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
Faria C; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
Gravelle P; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.; Department of Pathology, Institut Universitaire du Cancer de Toulouse, CEDEX 9, 31059 Toulouse, France.
Valero JG; Department of Hemato-Oncology, IDIBAPS, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), 28029 Madrid, Spain.
Dobaño-López C; Department of Hemato-Oncology, IDIBAPS, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), 28029 Madrid, Spain.
Morin R; IMACTIV-3D, 1 Place Pierre Potier, 31106 Toulouse, France.
Norlund M; IMACTIV-3D, 1 Place Pierre Potier, 31106 Toulouse, France.
Gomes A; IMACTIV-3D, 1 Place Pierre Potier, 31106 Toulouse, France.
Lagarde JM; IMACTIV-3D, 1 Place Pierre Potier, 31106 Toulouse, France.
Rossi C; CHU Dijon, Hématologie clinique, Hôpital François Mitterand, 21000 Dijon, France.
Bordenave J; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
Pieruccioni L; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, ENVT, 31100 Toulouse, France.
Rouquette J; RESTORE Research Center, Université de Toulouse, INSERM, CNRS, EFS, ENVT, 31100 Toulouse, France.
Matas-Céspedes A; Department of Hemato-Oncology, IDIBAPS, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), 28029 Madrid, Spain.
Fournié JJ; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
Ysebaert L; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.; Department of Hematology, Institut Universitaire du Cancer de Toulouse, CEDEX 9, 31059 Toulouse, France.
Laurent C; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.; Department of Pathology, Institut Universitaire du Cancer de Toulouse, CEDEX 9, 31059 Toulouse, France.
Pérez-Galán P; Department of Hemato-Oncology, IDIBAPS, 08036 Barcelona, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBERONC), 28029 Madrid, Spain.
Bezombes C; Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, CEDEX 1, 31037 Toulouse, France.; Université Toulouse III Paul-Sabatier, CEDEX 9, 31062 Toulouse, France.; ERL 5294 CNRS, CEDEX 4, 31055 Toulouse, France.; Institut Universitaire du Cancer-Oncopole de Toulouse, CEDEX 9, 31059 Toulouse, France.; Laboratoire d'Excellence 'TOUCAN-2', CEDEX 1, 31037 Toulouse, France.; Institut Carnot Lymphome CALYM, 69495 Pierre-Bénite, France.
DB Label
Database : MEDLINE
원문보기
Full Text Full Text (원문보기) PLinkFull Text (원문보기) Open Access (PubMed Central)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
1 2 
바구니보기

QUICK LINK

  • 희망도서신청
  • 대출/연장조회
  • 서가부재도서
  • 이용교육

마이메뉴추가

QRCode
  • 개인정보호정책
  • 이메일무단수집거부
  • 도서관이용문의

    • 도서관자치위원회  원격제어  Instagram  facebook  w  kakao 플친
500-757 광주광역시 북구 용봉로 77 TEL 062)530-3571~2(대출반납실) FAX 062)530-3529
Copyright@2013 CHONNAM NATIONAL UNIVERSITY LIBRARY, All Rights Reserved.
  • 14792
  • 128866968